Today, we are pleased to announce initiation of our global Phase 3 program for barzolvolimab, consisting of two Phase 3 trials designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment. These studies will enroll more than 1,800 patients suffering from CSU and include both biologic naïve and experienced patients. CEO Anthony Marucci and Dr. Marcus Maurer share insight into this milestone below. Full details here. https://lnkd.in/ezu99E_V
Celldex Therapeutics
Biotechnology Research
Hampton, NJ 10,213 followers
Developing antibodies that address devastating diseases for which available treatments are inadequate
About us
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.
- Website
-
http://www.celldex.com
External link for Celldex Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Hampton, NJ
- Type
- Public Company
- Specialties
- Immuno-oncology, Therapeutic antibodies, Immune system modulators, Immunotherapies, Oncology, Inflammatory Diseases, Inflammation, and Urticaria
Locations
-
Primary
53 Frontage Road
Suite 220
Hampton, NJ 08827, US
-
151 Martine Street
Fall River, MA 02723, US
-
119 Fourth Avenue
Needham, MA 02494, US
-
688 East Main Street
Suite 1A
Brandford, CT 06405, US
Employees at Celldex Therapeutics
Updates
-
We are thrilled to congratulate Dr. Marcus Maurer on his recognition from the European Academy of Allergy and Clinical Immunology - EAACI on his oral presentation of data from the Phase 2 clinical trial of barzolvolimab in chronic spontaneous #urticaria (CSU) at #EAACI2024. We are grateful for Dr. Maurer's continued support and advocacy for new, improved treatment options for those living with life-altering conditions like CSU.
-
-
At Celldex, introducing career paths in #STEM and other areas to the next generation is a priority to our team. In addition to local high school programs, each summer, we welcome college interns to our offices across all departments, where they have the opportunity to get hands-on experience in their areas of interest. We're excited to introduce our first three 2024 interns. Click through to hear more from each of them below.
-
We are pleased to present data demonstrating that barzolvolimab profoundly improves #angioedema at 12 weeks in the Phase 2 clinical trial in chronic spontaneous #urticaria (CSU). Angioedema is characterized by swelling of the deeper dermal layers of the skin and mucous membranes and is a painful, debilitating symptom of CSU that has a significant impact on quality of life. The data were presented this weekend by Dr. Marcus Maurer, Professor of Dermatology and Allergy at Charité - University Medicine Berlin at #EAACI2024. Full details here. https://lnkd.in/evv464V5
-
-
We are pleased to announce the first patient has been dosed in the Phase 2 clinical trial of barzolvolimab in #prurigonodularis (PN). PN is a chronic skin disease that causes hard, intensely itchy lumps/nodules to form on the skin. The itching can be intense causing people to scratch themselves to the point of bleeding or pain, which can form lesions and perpetuate the disease cycle. Learn more in the press release here. https://lnkd.in/eruVkZhM
-
-
Meet our newest Senior Clinical Data Manager, Francisco Ramirez! He shares more about himself and the path that led him to this career below.
Similar pages
Browse jobs
Stock
CLDX
NASDAQ
20 minutes delay
$40.22
0.67 (1.694%)
- Open
- 40.1
- Low
- 39.92
- High
- 40.695
Data from Refinitiv
See more info on